Show simple item record

dc.contributor.authorLinfante, Italo
dc.contributor.authorEtezadi, Vahid
dc.contributor.authorAndreone, Vincenzo
dc.contributor.authorDeLeo, Michael J. III
dc.contributor.authorAlehashemi, Sara
dc.contributor.authorShaw, Kate
dc.contributor.authorWakhloo, Ajay K.
dc.date2022-08-11T08:10:54.000
dc.date.accessioned2022-08-23T17:24:27Z
dc.date.available2022-08-23T17:24:27Z
dc.date.issued2010-06-01
dc.date.submitted2012-11-13
dc.identifier.citationJ Neurointerv Surg. 2010 Jun;2(2):135-8. <a href="http://dx.doi.org/10.1136/jnis.2009.001933">Link to article on publisher's site</a>
dc.identifier.issn1759-8478 (Linking)
dc.identifier.doi10.1136/jnis.2009.001933
dc.identifier.pmid21990593
dc.identifier.urihttp://hdl.handle.net/20.500.14038/49192
dc.description.abstractBACKGROUND AND PURPOSE: Thrombus formation during endovascular embolization of intracranial aneurysms occurs in 2.9%-6% of patients. Use of IIb/IIIA inhibitors such as abciximab or eptifibatide intravenously has been reported in management of this complication. Because the intra-arterial infusion of IIb/IIIA inhibitors may require lower doses to achieve thrombolysis, it may reduce the risk of haemorrhage. Therefore, we retrospectively analyze our database and review the literature. METHODS: This is a retrospective analysis of a prospectively acquired database of patients with ruptured or unruptured aneurysm treated intra-arterially for thrombus formation during endovascular coil embolization between July 2005 and August 2008. Patient demographics, aneurysmal characteristics, procedural, clinical outcome and complications were recorded. RESULTS: From July 2005 to August 2008, out of 184 patients who underwent coil embolization, 19 patients (15 smokers, 14 female, mean age 52) developed intraprocedural thrombus formation and received intra-arterial abciximab treatment. Mean aneurysm size was 6.6 mm+/-4.9 mm; neck size was 3.8 mm+/-2.1 mm. Eight (42.1%) aneurysms were ruptured. Most aneurysms (63.1%) were in anterior communicating and middle cerebral arteries. Thrombus was visualized in all cases by angiogram and treated intra-arterially with a mean dose of 10.5 mg+/-4.2. There were no periprocedural hemorrhagic complications. No deaths or other complications occurred during follow-up. CONCLUSION: Thrombus formation during coil embolization of intracranial aneurysms occurred more in women and smokers. Low doses of intra-arterial abciximab may be effective in the thromboembolic complications occurring during endovascular embolization of intracranial aneurysms.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21990593&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1136/jnis.2009.001933
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAneurysm, Ruptured
dc.subjectAntibodies, Monoclonal
dc.subjectEmbolization, Therapeutic
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectImmunoglobulin Fab Fragments
dc.subjectInfusions, Intra-Arterial
dc.subjectIntracranial Aneurysm
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectRetrospective Studies
dc.subjectThrombosis
dc.subjectTreatment Outcome
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleIntra-arterial abciximab for the treatment of thrombus formation during coil embolization of intracranial aneurysms
dc.typeJournal Article
dc.source.journaltitleJournal of neurointerventional surgery
dc.source.volume2
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/ssp/130
dc.identifier.contextkey3463755
html.description.abstract<p>BACKGROUND AND PURPOSE: Thrombus formation during endovascular embolization of intracranial aneurysms occurs in 2.9%-6% of patients. Use of IIb/IIIA inhibitors such as abciximab or eptifibatide intravenously has been reported in management of this complication. Because the intra-arterial infusion of IIb/IIIA inhibitors may require lower doses to achieve thrombolysis, it may reduce the risk of haemorrhage. Therefore, we retrospectively analyze our database and review the literature.</p> <p>METHODS: This is a retrospective analysis of a prospectively acquired database of patients with ruptured or unruptured aneurysm treated intra-arterially for thrombus formation during endovascular coil embolization between July 2005 and August 2008. Patient demographics, aneurysmal characteristics, procedural, clinical outcome and complications were recorded.</p> <p>RESULTS: From July 2005 to August 2008, out of 184 patients who underwent coil embolization, 19 patients (15 smokers, 14 female, mean age 52) developed intraprocedural thrombus formation and received intra-arterial abciximab treatment. Mean aneurysm size was 6.6 mm+/-4.9 mm; neck size was 3.8 mm+/-2.1 mm. Eight (42.1%) aneurysms were ruptured. Most aneurysms (63.1%) were in anterior communicating and middle cerebral arteries. Thrombus was visualized in all cases by angiogram and treated intra-arterially with a mean dose of 10.5 mg+/-4.2. There were no periprocedural hemorrhagic complications. No deaths or other complications occurred during follow-up.</p> <p>CONCLUSION: Thrombus formation during coil embolization of intracranial aneurysms occurred more in women and smokers. Low doses of intra-arterial abciximab may be effective in the thromboembolic complications occurring during endovascular embolization of intracranial aneurysms.</p>
dc.identifier.submissionpathssp/130
dc.contributor.departmentDepartment of Neurology
dc.contributor.departmentDepartment of Neurological Surgery
dc.contributor.departmentDepartment of Radiology
dc.source.pages135-8


This item appears in the following Collection(s)

Show simple item record